OncoMatch/Clinical Trials/NCT07193641
A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
Is NCT07193641 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies The systemic therapy for non small cell lung cancer.
Treatment: The systemic therapy — The goal of this clinical trial is to learn if spatially fractionated radiotherapy (SFRT) combined with standard systemic therapy can treat oligoprogressive non-small cell lung cancer (NSCLC) in patients who have progressed after at least one line of systemic therapy. The main question it aims to answer is: \- Can the combination of SFRT and standard systemic therapy improve progression-free survival (PFS) compared to standard systemic therapy alone? Participants will: * Undergo SFRT treatment for oligoprogressive lesions, with specific dose fractionation determined by the radiation oncologist based on clinical parameters. * Continue their standard systemic therapy, which may include chemotherapy, targeted therapy, or immunotherapy, as adjusted by their treating physician. * Have regular follow-up assessments, including imaging studies to evaluate treatment response and monitor for disease progression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy
having received and progressed after at least one line of systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
Must have received: targeted therapy
having received and progressed after at least one line of systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
Must have received: immunotherapy
having received and progressed after at least one line of systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
Lab requirements
Blood counts
hemoglobin ≥9.0 g/dL, ANC ≥1500/mm³, platelet count ≥100,000/mm³
Kidney function
creatinine ≤1.5x ULN (or GFR >60 mL/min if creatinine >1.5x ULN)
Liver function
total bilirubin ≤1.5x ULN (or direct bilirubin ≤ULN if total bilirubin >1.5x ULN), ALT and AST ≤2.5x ULN (or ≤5x ULN if liver involvement is present)
Adequate hematologic and biochemical profiles, including hemoglobin ≥9.0 g/dL, absolute neutrophil count (ANC) ≥1500/mm³, platelet count ≥100,000/mm³, total bilirubin ≤1.5 times the upper limit of normal (ULN) (or direct bilirubin ≤ULN if total bilirubin >1.5 times ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN (or ≤5 times ULN if liver involvement is present), and creatinine ≤1.5 times ULN (or glomerular filtration rate [GFR] >60 mL/min if creatinine >1.5 times ULN).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07193641 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy and targeted therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages